Inquis Medical Accelerates VTE Treatment with $75M Series C Funding for AVENTUS System
January 14, 2026, 3:36 pm
Location: United States
Employees: 11-50
Founded date: 2019
Total raised: $115M
Inquis Medical secured $75 million in Series C funding. An undisclosed strategic investor provided the substantial capital. This investment dramatically accelerates the nationwide commercial rollout of the innovative AVENTUS thrombectomy system. AVENTUS targets critical venous thromboembolic disease (VTE), effectively treating conditions like pulmonary embolism and deep vein thrombosis. Funds will significantly expand sales infrastructure, enhance specialized physician training, and advance the crucial product pipeline. This strategic move solidifies Inquis Medical's commercial trajectory and reinforces its commitment to groundbreaking VTE care. It marks a pivotal step in scaling advanced medical technology for broader patient benefit.
Inquis Medical, a pioneering medical device firm, has secured significant capital. The Menlo Park, California-based company closed a $75 million Series C financing round. This substantial investment will drive the next phase of its growth. A strategic investor, currently undisclosed, fueled this latest funding. This capital infusion signals strong confidence in Inquis Medical’s vision.
The new funds target several critical areas. A primary goal involves accelerating the nationwide commercial expansion of its AVENTUS thrombectomy system. This system is a flagship product. It addresses a pressing need in cardiovascular health. The company will also expand its sales footprint. Physician-training infrastructure will see considerable growth. This ensures widespread adoption and skilled use of the AVENTUS technology. Furthermore, capital will advance Inquis Medical's next-generation product pipeline. Innovation remains central to its strategy.
Inquis Medical focuses on mechanical thrombectomy. This procedure removes blood clots. The company targets venous thromboembolic disease (VTE). VTE encompasses serious conditions. Pulmonary embolism (PE) is one such life-threatening condition. Deep vein thrombosis (DVT) is another. AVENTUS offers a novel solution for these vascular challenges.
The AVENTUS system is engineered for superior performance. It enables directional aspiration. This precisely targets and extracts clots. A key innovation is its in-line blood reinfusion capability. This proprietary feature is autologous. It significantly minimizes blood loss during procedures. The design aims to improve clot removal efficiency. It also seeks to reduce overall procedural complexity. This benefits both patients and clinicians.
Advanced technology defines the AVENTUS platform. It integrates proprietary tissue-sensing technology. This provides real-time feedback to operators. Clinicians can differentiate between blood, clot, and vessel wall. This enhances safety and precision. The system also features an atraumatic dilator tip. An integrated navigation catheter further aids in precise delivery. These elements combine for a safer, more effective intervention.
The company achieved "transformative" milestones in 2025. Inquis Medical transitioned into a commercial-stage organization. It launched AVENTUS nationally. Regulatory clearance for pulmonary embolism (PE) expanded. This marked a significant achievement. Pivotal clinical data also saw publication. The Journal of the Society for Cardiovascular Angiography & Interventions published these findings.
The published clinical results were compelling. The study involved 130 intermediate-risk PE patients. AVENTUS demonstrated significant thrombus removal. It did so while minimizing blood loss. This was achieved through its integrated autologous blood reinfusion. Crucially, no device-related adverse events were reported. This robust evidence reinforces AVENTUS's clinical efficacy and safety profile.
VTE represents a substantial global health burden. Millions are affected annually. PE is a leading cause of cardiovascular death. Effective and safe thrombectomy solutions are vital. AVENTUS addresses this critical unmet medical need. Its innovative design promises improved patient outcomes. It offers a new standard of care.
This Series C funding follows prior investment success. Inquis Medical secured a $40 million Series B financing. That round concluded in August 2024. Marshall Wace led the Series B. The rapid succession of funding rounds highlights investor confidence. It also underscores the market's reception to AVENTUS.
Inquis Medical was founded in 2020. Its mission is clear: to redefine VTE treatment. The company’s leadership guides its strategic direction. It emphasizes the convergence of clinical excellence and technological innovation. This philosophy permeates product development and commercialization efforts.
The company’s strategic outlook is ambitious. It plans to expand its commercial footprint aggressively. Growing sales infrastructure is a priority. Enhancing physician-training infrastructure is equally important. This builds a robust support system. It also ensures proper use of the AVENTUS system. Continuous clinical evidence generation remains crucial. This commitment strengthens the product's foundation. Advancing its innovation roadmap secures future growth.
Inquis Medical is poised for significant market expansion. Its AVENTUS system offers a compelling solution for VTE. The latest capital infusion accelerates this trajectory. The company aims to make advanced tools accessible to physicians. This ultimately improves outcomes for patients battling venous thromboembolic disease. It represents a vital step forward in vascular medicine.
Inquis Medical, a pioneering medical device firm, has secured significant capital. The Menlo Park, California-based company closed a $75 million Series C financing round. This substantial investment will drive the next phase of its growth. A strategic investor, currently undisclosed, fueled this latest funding. This capital infusion signals strong confidence in Inquis Medical’s vision.
The new funds target several critical areas. A primary goal involves accelerating the nationwide commercial expansion of its AVENTUS thrombectomy system. This system is a flagship product. It addresses a pressing need in cardiovascular health. The company will also expand its sales footprint. Physician-training infrastructure will see considerable growth. This ensures widespread adoption and skilled use of the AVENTUS technology. Furthermore, capital will advance Inquis Medical's next-generation product pipeline. Innovation remains central to its strategy.
Inquis Medical focuses on mechanical thrombectomy. This procedure removes blood clots. The company targets venous thromboembolic disease (VTE). VTE encompasses serious conditions. Pulmonary embolism (PE) is one such life-threatening condition. Deep vein thrombosis (DVT) is another. AVENTUS offers a novel solution for these vascular challenges.
The AVENTUS system is engineered for superior performance. It enables directional aspiration. This precisely targets and extracts clots. A key innovation is its in-line blood reinfusion capability. This proprietary feature is autologous. It significantly minimizes blood loss during procedures. The design aims to improve clot removal efficiency. It also seeks to reduce overall procedural complexity. This benefits both patients and clinicians.
Advanced technology defines the AVENTUS platform. It integrates proprietary tissue-sensing technology. This provides real-time feedback to operators. Clinicians can differentiate between blood, clot, and vessel wall. This enhances safety and precision. The system also features an atraumatic dilator tip. An integrated navigation catheter further aids in precise delivery. These elements combine for a safer, more effective intervention.
The company achieved "transformative" milestones in 2025. Inquis Medical transitioned into a commercial-stage organization. It launched AVENTUS nationally. Regulatory clearance for pulmonary embolism (PE) expanded. This marked a significant achievement. Pivotal clinical data also saw publication. The Journal of the Society for Cardiovascular Angiography & Interventions published these findings.
The published clinical results were compelling. The study involved 130 intermediate-risk PE patients. AVENTUS demonstrated significant thrombus removal. It did so while minimizing blood loss. This was achieved through its integrated autologous blood reinfusion. Crucially, no device-related adverse events were reported. This robust evidence reinforces AVENTUS's clinical efficacy and safety profile.
VTE represents a substantial global health burden. Millions are affected annually. PE is a leading cause of cardiovascular death. Effective and safe thrombectomy solutions are vital. AVENTUS addresses this critical unmet medical need. Its innovative design promises improved patient outcomes. It offers a new standard of care.
This Series C funding follows prior investment success. Inquis Medical secured a $40 million Series B financing. That round concluded in August 2024. Marshall Wace led the Series B. The rapid succession of funding rounds highlights investor confidence. It also underscores the market's reception to AVENTUS.
Inquis Medical was founded in 2020. Its mission is clear: to redefine VTE treatment. The company’s leadership guides its strategic direction. It emphasizes the convergence of clinical excellence and technological innovation. This philosophy permeates product development and commercialization efforts.
The company’s strategic outlook is ambitious. It plans to expand its commercial footprint aggressively. Growing sales infrastructure is a priority. Enhancing physician-training infrastructure is equally important. This builds a robust support system. It also ensures proper use of the AVENTUS system. Continuous clinical evidence generation remains crucial. This commitment strengthens the product's foundation. Advancing its innovation roadmap secures future growth.
Inquis Medical is poised for significant market expansion. Its AVENTUS system offers a compelling solution for VTE. The latest capital infusion accelerates this trajectory. The company aims to make advanced tools accessible to physicians. This ultimately improves outcomes for patients battling venous thromboembolic disease. It represents a vital step forward in vascular medicine.